Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study

Gabes, Michaela; Ragamin, Aviël; Baker, Arabella; Kann, Gesina; Donhauser, Theresa; Gabes, Daniela; Howells, Laura; Kim, Thomas; Oosterhaven, Jart A F; Pasmans, Suzanne G.M.A.; Schuttellaar, Marie-L; Apfelbacher, Christian

doi:10.1111/bjd.21767

Cited by 7 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The content validity of RECAP has also been assessed in various studies ( 19 – 21 , 28 , 29 ). The self-reported version of RECAP has been reported to be appropriate for use from the age of 12 years ( 20 ).…”

Section: Discussionmentioning

confidence: 99%

“…The HOME VII meeting in 2019 recommended the use of the Atopic Dermatitis Control Test (ADCT) or RECAP as measures for long-term control as part of the core set of outcomes to be reported in all eczema trials (16,17). RECAP was developed and validated in English, but currently other language versions of RECAP such as German, Dutch, and Spanish versions were also considered comprehensible, and adults, as well as parents of affected children (19)(20)(21).…”

Section: Numerous Outcome Measures Have Been Developedmentioning

confidence: 99%

See 1 more Smart Citation

Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting

Yew,

Phuan,

Zhao

et al. 2024

Acta Derm Venereol

Self Cite

View full text Add to dashboard Cite

Recap of atopic eczema (RECAP) is a self-reported 7-item questionnaire recommended by the Harmonising Outcome Measures in Eczema initiative to measure eczema control. As RECAP has not been validated in a real-world clinical population in Asia, RECAP was investigated as a measure of eczema control in Singapore. Patients with atopic eczema at the National Skin Centre from July 2019 to January 2020 were included for analysis. Both patient- and physician-reported outcome measures were available for correlation analyses. Correlation analysis was also performed to investigate construct validity, and floor or ceiling effects of RECAP. A total of 260 atopic eczema patients aged between 15 and 87 years were recruited. There were minimal floor and ceiling effects for RECAP scores. There were strong, significant correlations of RECAP with POEM (r = 0.84, p < 0.001) and DLQI (r = 0.81, p < 0.001). Correlation with SCORAD was moderate (r = 0.60, p < 0.001). Correlations remained similar after age, gender, and ethnicity adjustments. Discriminative validity was demonstrated by a significant linear trend of increasing RECAP scores with increasing eczema severity. RECAP demonstrates good discriminative and construct validity evidenced by strong correlations with symptoms and quality of life and moderate correlations with eczema signs. RECAP is useful to measure eczema control in Singapore.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Numerous Outcome Measures Have Been Developedmentioning

confidence: 99%

Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting

Yew,

Phuan,

Zhao

et al. 2024

Acta Derm Venereol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The 2 long-term eczema control instruments in the latter study showed strong correlation. Additionally, Gabes et al found the self-reported English, German, and Dutch RECAP relevant and comprehensible in young people from 12 years of age ( 13 ).…”

Section: Discussionmentioning

confidence: 99%

Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population

Sigurdardottir,

Alsterholm,

Andersson

et al. 2024

Acta Derm Venereol

View full text Add to dashboard Cite

A Swedish translation of the patient-reported outcome measure for assessing long-term control of atopic dermatitis, Recap of atopic eczema (RECAP), has not been validated. Cross-cultural translation and multi-centre validation of the translated RECAP questionnaire were therefore performed. Disease severity was assessed using the validated Investigator Global Assessment Scale for atopic dermatitis (vIGA-ADTM). The Swedish RECAP was completed by 208 individuals aged 16 years or older with a median age of 36 years (interquartile range [IQR] 27–48). The participants considered the questionnaire suitable for assessing eczema control. The median RECAP score (range 0–28) was 12 (IQR 5–19). The mean and median vIGA-ADTM scores (range 0–4) were 2 (standard deviation [SD] 2) and 3 (IQR 2–4), respectively. A correlation between RECAP and the vIGA-ADTM was observed (p < 0.001). There was no significant change in scores for participants who answered the questionnaire twice within 14 days. Over time, improved or worsened eczema, as evaluat-ed by vIGA-ADTM, affected RECAP scores significantly (p < 0.001). The study suggests that RECAP can assess AD control in a Swedish clinical setting and shows -acceptable reliability.

show abstract

Determining the minimal important change of the recap of atopic eczema (RECAP) instrument in clinical trials

Baker,

Stuart,

Howells

et al. 2024

Skin Health and Disease

View full text Add to dashboard Cite

BackgroundThe Recap of atopic eczema (RECAP) is a patient‐reported instrument designed to assess eczema control. There is a lack of evidence on the interpretability of change scores in clinical trials.ObjectivesTo calculate the smallest detectable change (SDC) in RECAP and estimate the minimal important change (MIC) for RECAP using various calculation methods in three eczema clinical trial datasets.MethodsIn this study, four anchor‐based methods (within‐person score change, between‐patient score change, predictive modelling, receiver operating characteristic curve) and a distribution‐based method (effect size) was used to determine the MIC of RECAP. The trial datasets involved children (0–12 years), young people (13–25 years) and adults (>25 years) with all eczema severities.ResultsA total of 698 participants were included in this study. The SDC was between 1.74 and 1.80. For the anchor‐based methods, the patient global assessment anchor provided MIC values ranging from 2.35 to 3.94 and the patient oriented eczema measure anchor yielded values between 1.11 and 3.62. The MIC for the distribution‐based method ranged from 2.66 to 3.06, respectively.ConclusionsThe interpretability of RECAP was improved by establishing MIC values and the following thresholds are suggested for interpreting changes in RECAP scores: <2.0 points is possibly a measurement error; 2.0–2.9 points denotes a small improvement that may be clinically relevant; 3.0–3.9 points indicates an improvement that is likely to be clinically important and ≥4.0 points is highly likely to represent a clinically important change.

show abstract

Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study

Abstract: and Laura Howells were involved in the original development of Recap of atopic eczema (RECAP). All three are members of the executive committee of the Harmonising Outcome Measures for Eczema (HOME) initiative. Laura Howells has acted as a consultant for the University of Oxford on an

Cited by 7 publications

References 28 publications

Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting

Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting

Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population

Determining the minimal important change of the recap of atopic eczema (RECAP) instrument in clinical trials

Contact Info

Product

Resources

About

Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study

Abstract: and Laura Howells were involved in the original development of Recap of atopic eczema (RECAP). All three are members of the executive committee of the Harmonising Outcome Measures for Eczema (HOME) initiative. Laura Howells has acted as a consultant for the University of Oxford on an

Cited by 7 publications

References 28 publications

Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting

Validation of the Recap of Atopic Eczema (RECAP) Measurement Instrument for Eczema Control in Adult Patients in an Asian Clinical Setting

Cross-Cultural Validation of the RECAP of Atopic Eczema Question­naire in a Swedish Population

Determining the minimal important change of the recap of atopic eczema (RECAP) instrument in clinical trials

Contact Info

Product

Resources

About

Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population